Intercept names senior VP, medical affairs
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic underserved liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH), has appointed Dr Juan Carlos Lopez-Talavera senior vice-president of medical affairs. Dr Lopez-Talavera was most recently head of hepatology R&D and vice-president of medical affairs at AbbVie, where he was responsible for all medical affairs activities supporting the global launch of AbbVie's regimen for the treatment of hepatitis C.